The secondary leukemias: Challenges and research directions

Journal of the National Cancer Institute

Volumn 88, Issue 7, 1996, Pages 407-418

  Smith, Malcolm A ^a   McCaffrey, Ronald P ^b   Karp, Judith E ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIPODOPHYLLOTOXIN DERIVATIVE; GYRASE INHIBITOR; MUTAGENIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG INDUCED CANCER; HIGH RISK POPULATION; HUMAN; LEUKEMOGENESIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; HUMANS; INCIDENCE; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS;

EID: 0029929429     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.7.407     Document Type: Review

References (199)

1. Aksoy M, Dincol K, Erdem S, Dincol G. Acute leukemia due to chronic exposure to benzene. Am J Med 1972;52:160-5.
2. Kjeldsberg C, Ward H. Leukemia in arsenic poisoning. Ann Intern Med 1972;77:935-7.
3. Mitelman F, Brandt L, Nilsson P. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood 1978; 52:1229-37.
4. Golomb HM, Alimena G, Rowley JD, Vardiman JW, Testa JR, Sovik C. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 1982;60:404-11.
5. Kaldor JE, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's disease [see comment citations in Medline]. N Engl J Med 1990;322:7-13.
6. Rowley J, Golomb H, Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood 1977;50:759-70.
7. Pedersen-Bjergaard J, Larsen S. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982;307:965-71.
8. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780-6.
9. Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 1991;78:2982-8.
10. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993;82:3705-11.
11. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
12. Hunger SP, Tkachuk DC, Amylon MD, Link MP, Carroll AJ, Welborn JL, et al. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities [see comment citation in Medline]. Blood 1993;81:3197-202.
13. Levine E, Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
14. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comment citation in Medline]. Blood 1994;83:3780-6.
15. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991;9:1575-9.
16. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood 1994; 84:3253-60.
17. Le Beau MM, Espinosa R 3d, Neuman WL, Stock W, Roulston D, Larson RA, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A 1993;90:5484-8.
18. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968-70.
19. Fisher E, Scambler P: Human haploinsufficiency - one for sorrow, two for joy [news]. Nat Genet 1994;7:5-7.
20. Halford S, Wadey R, Roberts C, Daw SC, Whiting JA, O'Donnell H, et al. Isolation of a putative transcriptional regulator from the region of 22q11 deleted in DiGeorge syndrome, Shprintzen syndrome and familial congenital heart disease. Hum Mol Genet 1993;2:2099-107.
21. Ton CC, Hirvonen HH, Miwa H, Weil MM, Monaghan P, Jordan T, et al. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell 1991;67:1059-74.
22. Vortkamp A, Gessler M, Grzeschik KH. GLI3 zinc-finger gene interrupted by translocations in Greig syndrome families. Nature 1991; 352:539-40.
23. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-7.
24. Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia [see comment citation in Medline]. N Engl J Med 1989;321:136-42.
25. DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med 1989;110:740-2.
26. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994;23:86-98.
27. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259:13560-6.
28. Liu L, Wang J. Biochemistry of DNA topoisomerases and their poisons. In: Potmesil M, Kohn K, editors. DNA topoisomerases in cancer. New York: Oxford University Press, 1991:13-22.
29. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7.
30. Capranico G, Kohn KW, Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990;18:6611-9.
31. Chatterjee S, Trivedi D, Pelzold SJ, Berger NA. Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Cancer Res 1990; 50:2713-8.
32. Berger NA, Chatterjee S, Schmotzer JA, Helms SR. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci U S A 1991;88:8740-3.
33. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias [published erratum appears in Proc Natl Acad Sci U S A 1992;88:10735-9]. Proc Natl Acad Sci U S A 1991;88:10735-9.
34. Cimino G, Moir DT, Canaani O, Williams K, Crist WM, Katzav S, et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res 1991;51:6712-4.
35. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA, et al. A trithorax - like gene is interrupted by chromosome 11q23 translocations in acute leukaemias [published erratum appears in Nat Genet 1993;4:431]. Nat Genet 1992;2:113-8.
36. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 abnormalities [see comment citations in Medline]. N Engl J Med 1993;329:958-9.
37. Young B. Cytogenetic and molecular analysis of chromosome 11q23 abnormalities in leukaemia. Baillières Clin Haematol 1992;5:881.
38. Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 1994;86:1678-80.
39. Schichman SA, Caligiuri MA, Strout MP, Carter SL, Gu Y, Canaani E, et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res 1994;54:4277-80.
40. Felix CA, Hosler MR, Winick NJ, Masterson ME, Wilson AE, Lange BJ, et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995;85:3250-6.
41. Gu Y, Cimino G, Alder H, Nakamura T, Prasad R, Canaani O, et al. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc Natl Acad Sci U S A 1992;89:10464-8.
42. Negrini M, Felix CA, Martin C, Lange BJ, Nakamura T, Canaani E, et al. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 1993;53:4489.
43. Jaeger U, Karth GD, Knapp S, Friedl J, Laczika K, Kusec R. Molecular mechanism of the t(14;18) - a model for lymphoid-specific chromosomal translocations. Leuk Lymphoma 1994;14:197-202.
44. Knapp S, Delle Karth G, Friedl J, Purtscher B, Mitterbauer G, Domer PH, el al. Guanine-rich (GGNNGG) elements at chromosomal breakpoints interact with a loop-forming, single-stranded DNA-binding protein. Oncogene 1994:1501-5.
45. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-8.
46. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991;51:4909-16.
47. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morita T, et al. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 1994;126:1341-51.
48. Ishimi Y, Ishida R, Andoh T. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro. Mol Cell Biol 1992;12:4007-14.
49. Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res 1992;16:1113-23.
50. Caffrey EA, Daker MG, Horton JJ. Acute myeloid leukaemia after treatment with razoxane. Br J Dermatol 1985;113:131-4.
51. Steinman HK, Griffiths WA, Levene GM. Methotrexate in lieu of razoxane for incapacitating psoriasis [letter]. Lancet 1984;1:458-9.
52. Price CM, Hagger D, Evans M, Kanfer EJ, Shepherd J, Topham C. Sister chromatid exchange (SCE) frequency in lymphocytes of patients with colorectal carcinoma treated with razoxane. Cancer Detect Prev 1992; 16:221-3.
53. Bhavnani M, Wolstenholme RJ. Razoxane and acute promyelocytic leukaemia [letter]. Lancet 1987;2:1085.
54. Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994;12:530-42.
55. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
56. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
57. Degrassi F, DeSalvia R, Tanzerella C, Palitti F. Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutat Res 1989;211:125-30.
58. Hashimoto H, Chatterjee S, Berger N. Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1995;1:369-76.
59. Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, et al. Effective immunochemotherapy of CALLA+Cmu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992;79:3116-29.
60. Uckun FM, Downing JR, Chelstrom LM, Gunther R, Ryan M, Simon J, et al. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency, Blood 1994;84:859-65.
61. Sancar A. Mechanisms of DNA excision repair. Science 1994;266:1954-5.
62. Modrich P. Mismatch repair, genetic stability, and cancer. Science 1994;266:1959-60.
63. Marx J. DNA repair comes into its own [news; comment]. Science 1994;26:728-30.
64. Marx J. New link found between p53 and DNA repair [news; comment]. Science 1994;266:1321-2.
65. O'Donovan A, Davies AA, Moggs JG, West SC, Wood RD. XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature 1994;371:432-5.
66. Tanaka K, Wood RD. Xeroderma pigmentosum and nucleotide excision repair of DNA. Trends Biochem Sci 1994;19:83-6.
67. Guzder SN, Sung P, Prakash L, Prakash S. Yeast DNA-repair gene RAD14 encodes a zinc metalloprotein with affinity for ultraviolet-damaged DNA. Proc Natl Acad Sci U S A 1993;90:5433-7.
68. Jones CJ, Wood RD: Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. Biochemistry 1993; 32:12096-104.
69. O'Donovan A, Scherly D, Clarkson SG, Wood RD. Isolation of active recombinant XPG protein, a human DNA repair endonuclease. J Biol Chem 1994;269:15965-8.
70. Park C, Sancar A. Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins. Proc Natl Acad Sci U S A 1994;91:5017-21.
71. Guzder SN, Sung P, Bailly V, Prakash L, Prakash S. RAD25 is a DNA helicase required for DNA repair and RNA polymerase II transcription [if«• comment citation in Medline]. Nature 1994;369:578-81.
72. Ma L, Siemssen E, Noteborn H, van der Eb AJ. The xeroderma pigmentosum group B protein ERCC3 produced in the baculovirus system exhibits DNA helicase activity. Nucleic Acids Res 1994;22:4095-102.
73. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-5.
74. Hanawalt P. Transcription-coupled repair and human disease. Science 1994;266:1957-8.
75. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JH, et al. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor [see comment citations in Medline]. Science 1993;260:58-63.
76. Donahue BA, Yin S, Taylor JS, Reines D, Hanawalt PC. Transcript cleavage by RNA polymerase II arrested by a cyclobutane pyrimidine dimer in the DNA template. Proc Natl Acad Sci U S A 1994;91:8502-6.
77. Henning KA, Li L, Iyer N, McDaniel LD, Reagan MS, Legerski R, et al. The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995;82:555-64.
78. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D, Hoeijmakers JH. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 1992;71:939-53.
79. Troelstra C, Hesen W, Bootsma D, Hoeijmakers JH. Structure and expression of the excision repair gene ERCC6, involved in the human disorder Cockayne's syndrome group B. Nucleic Acids Res 1993;21:419-26.
80. Rampino NJ, Bohr VA. Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymerase [published erratum appears in Proc Natl Acad Sci U S A 1995;92:5249]. Proc Natl Acad Sci U S A 1994;91:10977-81.
81. Mellon I, Spivak G, Hanawalt P. Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 1987;51:241-9.
82. Beecham EJ, Mushinski JF, Shacter E, Potter M, Bohr VA. DNA repair in the c-myc proto-oncogene locus: possible involvement in susceptibility or resistance to plasmacytoma induction in BALB/c mice. Mol Cell Biol 1991;11:3095-4004.
83. Evans MK, Robbins JH, Ganges MB, Tarone RE, Nairn RS, Bohr VA. Gene-specific DNA repair in xeroderma pigmentosum complementaton groups A, C, D and F. Relation to cellular survival and clinical features. J Biol Chem 1993;268:4839-47.
84. Evans MK, Taffe BG, Harris CC, Bohr VA. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res 1993;53:5377-81.
85. Dumaz N, Drougard C, Sarasin A, Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc Natl Acad Sci U S A 1993;90:10529-33.
86. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991;88:10124-8.
87. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
88. Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK, et al. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci U S A 1994;91.360-4.
89. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984;4:1689-94.
90. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
91. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-5.
92. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
93. Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 1995;10:1053-9.
94. Smith ML, Fornace AJ Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 1995;7:69-75.
95. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995;10:188-95.
96. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
97. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994;8:666-77.
98. Kastan MB, Zhan Q, EI-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective ataxia-telangiectasis. Cell 1992;71:587-97.
99. Waldmann TA, Misiti J, Nelson DL, Kraemer KH. Ataxia-telangiectasia: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. Ann Intern Med 1983;99:367-79.
100. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vangaite L, et al. A single gene with a product similar to PI 3-kinase [see comment citation in Medline]. Science 1995;268:1749-53.
101. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995;270:50-1.
102. Zakian VA. ATM-related genes: what do they tell us about functions of the human gene? Cell 1995;82:685-7.
103. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR. Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993; 73:585-96.
104. Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R, Hall MN. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 1994;5:105-18.
105. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-22.
106. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-8.
107. Guzder SN, Qiu H, Sommers CH, Sung P, Prakash L, Prakash S. DNA repair gene RAD3 of S. cerevisiae is essential for transcription by RNA polymerase II. Nature 1994;367:91-4.
108. al-Khodairy F, Carr AM. DNA repair mutants defining G2 checkpoint pathways in Schizosaccharomyces pombe. EMBOJ 1992;11:1343-50.
109. Naegeli H, Modrich P, Friedberg EC. The DNA helicase activities of Rad3 protein of Saccharomyces cerevisiae and helicase II of Escherichia coli are differentially inhibited by covalent and noncovalent DNA modifications. J Biol Chem 1993;268:10386-92.
110. Canman CE, Wolff AC, Chen CY, Fornace AJ Jr, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994;54:5054-8.
111. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994;14:1815-23.
112. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23.
113. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
114. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
115. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases [see comment citations in Medline]. Nature 1993;366:701-4.
116. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1994;91:5320-4.
117. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995;81:1013-20.
118. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A 1995;92:9455-9.
119. Wang X, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994;91:2230-4.
120. Tsurimoto T, Stillman B. Functions of replication factor C and proliferating-cell nuclear antigen: functional similarity of DNA polymerase accessory proteins from human cells and bacteriophage T4. Proc Natl Acad Sci U S A 1990;87:1023-7.
121. Lee SH, Hurwitz J. Mechanism of elongation of primed DNA by polymerase delta, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci U S A 1990;87:5672-6.
122. Burgers PM, Yoder BL. ATP-independent loading of the proliferating cell nuclear antigen requires DNA ends. J Biol Chem 1993;268:19923-6.
123. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by intereaction with PCNA [see comment citation in Medline]. Nature 1994;369:574-8.
124. Li R, Waga S, Hannon G, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-7.
125. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A 1994;91:8655-99.
126. Aboussekhra A, Biggerstaff M, Shivji M, Vilpo JA, Moncollin V, Podust VN, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995;80:859-68.
127. Nichols AF, Sancar A. Purification of PCNA as a nucleotide excision repair protein [corrected and republished with original paging, article originally printed in Nucleic Acids Res 1992;20:2441-6]. Nucleic Acids Res 1992;20:3559-64.
128. Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-74.
129. Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace AJ Jr. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem 1993;268:24385-93.
130. Zhan Q, Lord KA, Alamo I Jr, Hollander MC, Carrier F, Ron D, et al. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 1994;14:2361-71.
131. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, et al. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen [see comment citation in Medline]. Science 1994;266:1376-80.
132. Shields PG. Pharmacogenetics: detecting sensitive populations. Environ Health Perspect 102 Suppl 1994;11:81-7.
133. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995;5:59-63.
134. Albertini RJ, Nicklas JA, O'Neill JP, Robison SH. In vivo somatic mutations in humans: measurement and analysis. Annu Rev Genet 1990; 24:305-26.
135. Albertini RJ, Nicklas JA, Fuscoe JC, Skopek TR, Banda RF, O'Neill JP, et al. In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ Health Perspect 1993;99:135-41.
136. Bigbee WL, Langlois RG, Stanker LH, Vanderlaan M, Jensen RH. Flow cytometric analysis of erythrocyte populations in Tn syndrome blood using monoclonal antibodies to glycophorin A and the Tn antigen. Cytometry 1990;11:261-71.
137. Grant SG, Bigbee WL. In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus: phenotypic variation encompassing both gene-specific and chromosomal mechanisms. Mutat Res 1993;288:163-72.
138. Bigbee WL, Wyrobek AJ, Langlois RG, Jensen RH, Everson RB. The effect of chemotherapy on the in vivo frequency of glycophorin A 'null' variant erythrocytes. Mutat Res 1990;240:165-70.
139. Mott MG, Boyse J, Hewitt M, Radford M. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukaemia? [see comment citations in Medline] Lancet 1994;343:828-9.
140. Grant SG, Bigbee WL. Bone marrow somatic mutation after genotoxic cancer therapy [letter; comment] [published erratum appears in Lancet 1994;344:415]. Lancet 1994;343:1507-8.
141. Perera FP, Motzer RJ, Tang D, Reed E, Parker R, Warburton D, et al. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res 1992;52:3558-65.
142. Ammenheuser MM, Au WW, Whorton EJ Jr, Belli JA, Ward JB Jr. Comparison of hprt variant frequencies and chromosome aberration frequencies in lymphocytes from radiotherapy and chemotherapy patients: a prospective study. Environ Mol Mutagen 1991;18:126-35.
143. Tates AD, van Dam FJ, Natarajan AT, Zwinderman AH, Osanto S. Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat Res 1994;307: 293-306.
144. Kelsey KT, Caggana M, Mauch PM, Coleman CN, Clark JR, Liber HL. Mutagenesis after cancer therapy. Environ Health Perspect 1993;101 Suppl 3:177-84.
145. Branda RF, O'Neill JP, Sullivan LM, Albertini RJ. Factors influencing mutation at the hprt locus in T-lymphocytes: women treated for breast cancer. Cancer Res 1991;51:6603-7.
146. Albertini RJ, Nicklas JA, O'Neill JP. Somatic cell gene mutations in humans: biomarkers for genotoxicity. Environ Health Perspect 1993;101 Suppl 3:193-201.
147. Morris T, Thacker J. Formation of large deletions by illegitimate recombination in the HPRT gene of primary human fibroblasts. Proc Natl Acad Sci U S A 1993;90:1392-6.
148. Fuscoe JC, Zimmerman LJ, Lippert MJ, Nicklas JA, O'Neill JP, Albertini RJ. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res 1991;51:6001-5.
149. Olden K. Mutagen hypersensitivity as a biomarker of genetic predisposition to carcinogenesis [editorial] [see comment citation in Medline]. J Natl Cancer Inst 1994;86:1660-1.
150. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992;98:87-94.
151. Ketterer B, Meyer D, Clark A. Soluble glutathione transferase isozymes. In: Sies H, Ketterer B, editors. Glutathione conjugation. London: Academic Press, 1988:73-135.
152. Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 1990;48:357-69.
153. Pemble S, Schroeder K, Spencer SR, Meyer DJ, Hallier E, Bolt H, et al. Human glutathione S-transferase theta (GSTTI): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
154. van Poppel G, de Vogel N, van Balderen PJ, Kok FJ. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme mu. Carcinogenesis 1992;13:303-5.
155. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993;53:3486-92.
156. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo [see comment citation in Medline]. J Natl Cancer Inst 1995; 87:902-7.
157. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers [published erratum appears in Carcinogenesis 1994;15:1767]. Carcinogenesis 1994;15:813-5.
158. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:589-94.
159. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990;11:33-6.
160. Zhong S, Howie AF, Ketter B, Taylor J, Hayes JD, Beckett GJ, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991;12:1533-7.
161. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender, and histological cancer types. Carcinogenesis 1994;15:1785-90.
162. Kihara M, Kihara M, Noda K, Okamoto N. Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Lett 1993;71:151-5.
163. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 1995;87:1246-53.
164. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993;85: 1159-64.
165. Katoh T, Inatomi H, Nagaoka A, Sugita A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis 1995;16:655-7.
166. Daly A, Thomas D, Cooper J, Peason WR, Neal DE, Idle JR. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. Br Med J 1993;307:481-2.
167. Lafuente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993;68:49-54.
168. Chern H, Romkes-Sparks M, Hu J. Persad R, Sibley GA, Smith PJ, et al. Homozygous deleted genotype of glutathione S-transferase M1 increases susceptibility to aggressive bladder cancer. Proc Am Assoc Cancer Res 1994;35:1700(abstr).
169. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993;14:1821-4.
170. Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. Br J Cancer 1995;72:324-6.
171. Strange RC, Fryer AA, Matharoo B, Zhao L, Broome J, Campbell DA, et al. The human glutathione S-transferases: comparison of isoenzyme expression in normal and astrocytoma brain. Biochim Biophys Acta 1992;1139:222-8.
172. Wiencke J, Wrensch M, Miike R, Kelsey KT. Early onset brain cancer in women associated with glutathione S-transferase mu gene deletion: a population-based study. Proc Am Assoc Cancer Res 1995;36:118 (abstr).
173. Chen H, Sandler D, Taylor JA, Watson M, Shore DL, Lin E, et al. Carcinogen metabolism polymorphism and myelodysplaslic syndrome. Proc Am Assoc Cancer Res 1995;36:133 (abstr).
174. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 1993;14:77-87.
175. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
176. Mooney L, Bell D, Lucier G, Ottman R, Santella RM, Tsai WY, et al. Modulation of DNA adducts in heavy smokers by genetic factors. Proc Am Assoc Cancer Res 1995;36:120 (abstr).
177. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993;53:2994-9.
178. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, et al. Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. CEBP 1992;1:485-9.
179. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp1 restriction fragment polymorphism and incidence of lung can-cer in a Norwegian population. Pharmacogenetics 1991;1:20-5.
180. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 1993;2:481-5.
181. (181) Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 1994;72:240-8.
182. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smokederived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991;12:1197-201.
183. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, et al. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 1993;3:28-39.
184. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
185. Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, et al. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 1992;98:101-5.
186. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984;312:169-70.
187. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Isaag HJ, et al. Lung cancer and the debrisoquine metabolic phenotype [see comment citations in Medline], J Natl Cancer Inst 1990;82:1264-72.
188. Agundez JA, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, et al. Debrisoquin oxidation genotype and susceptibility to lung cancer. Pharmacol Ther 1994;55:10-4.
189. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993;3:19-27.
190. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC, Pass HI, et al. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:41-8.
191. Tefre T, Daly AK, Armstrong M, Leathart JB, Idle JR, Brogger A, et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994;4:47-57.
192. Caporaso N, DeBaun MR, Rothman N. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 1995;5:S129-S134.
193. Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriquez-Lescure A, Diaz-Rubio E, et al. CYP2D6 genes and risk of liver cancer. Lancet 1995;345:830-1.
194. Kawajiri K, Watanabe J, Eguchi H, Hayashi S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics 1995;5:S70-3.
195. Minchin RF, Kadlubar FF, Ilett KF. Role of acetylation in colorectal cancer. Mutat Res 1993;290:35-42.
196. Lang NP, Butler MA, Massengill JF, Lawson M, Stotts RC, Hauer-Jensen M, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994;3:675-82.
197. Kaderlik KR, Kadlubar FF. Metabolic polymorphisms and carcinogenDNA adduct formation in human populations. Pharmacogenetics 1995;5:S108-17.
198. DeCillis A, Anderson S, Wickerham D, Brown A, Fisher B, contributing investigators. Acute myeloid leukemia (AMD) in NSABP B-25. Proc ASCO 1995;14:98 (abstr).
199. Smith MA, Rubinstein L, Cazenave L, Ungerleider RS, Maurer HM, Heyn R, et al. Report of the Cancer Therapy Evaluation Program (CTEP) monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 1993;85:554-8.